Balyasny Asset Management
AMRX icon

Balyasny Asset Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Balyasny Asset Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$983K Sell
79,123
-610,744
-89% -$8.2M ﹤0.01% 2088
2025
Q4 		$8.69M Buy
689,867
+43,681
+7% +$500K 0.01% 1098
2025
Q3 		$6.47M Buy
646,186
+446,197
+223% +$4M 0.01% 1258
2025
Q2 		$1.62M Sell
199,989
-519,091
-72% -$3.91M ﹤0.01% 1841
2025
Q1 		$6.03M Buy
719,080
+546,767
+317% +$4.56M 0.01% 1158
2024
Q4 		$1.36M Buy
+172,313
New +$1.45M ﹤0.01% 1822
2023
Q4 		– Sell
-29,594
Closed -$125K – 2466
2023
Q3 		$125K Buy
+29,594
New +$110K ﹤0.01% 2099
2020
Q2 		– Sell
-24,151
Closed -$84K – 1106
2020
Q1 		$84K Buy
+24,151
New +$102K ﹤0.01% 1086
2019
Q3 		– Sell
-32,834
Closed -$235K – 1141
2019
Q2 		$235K Sell
32,834
-95,287
-74% -$974K ﹤0.01% 1377
2019
Q1 		$1.81M Buy
128,121
+60,605
+90% +$801K 0.01% 851
2018
Q4 		$913K Sell
67,516
-4,958
-7% -$89.3K 0.01% 928
2018
Q3 		$1.61M Buy
+72,474
New +$1.53M 0.01% 1051

Other funds holding AMRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Balyasny Asset Management's AMRX Position: Q1 2026 in Review

Balyasny Asset Management reduced its Amneal Pharmaceuticals (AMRX) stake by 89% in Q1 2026, selling an estimated $8.2M and leaving 79,123 shares worth $983K. The position accounts for ﹤0.01% of the portfolio, ranked #2088.

Balyasny Asset Management first reported a position in AMRX in Q3 2018 and has held it in 12 quarters since. The position peaked at $8.69M in Q4 2025. 316 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

  • Balyasny Asset Management held 79,123 shares of Amneal Pharmaceuticals worth $983K as of Q1 2026.
  • Balyasny Asset Management sold 610,744 Amneal Pharmaceuticals shares in Q1 2026, an estimated $8.2M.
  • Amneal Pharmaceuticals made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2088 holding.
  • Balyasny Asset Management first reported a position in Amneal Pharmaceuticals in Q3 2018 and has held it in 12 quarters since.
  • Balyasny Asset Management's Amneal Pharmaceuticals position peaked at $8.69M in Q4 2025.
  • 316 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.